COMMUNIQUÉS West-GlobeNewswire

Alignment Healthcare Continues to Deliver High-Quality Medicare Advantage Plans, 4 Stars or Greater for 98% of Members in 2025
11/10/2024
Medicare Advantage company retains 5- out of 5-star rating in North Carolina and Nevada, California PPO earns 4.5 stars ORANGE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) [...]
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
11/10/2024
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/10/2024
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat
11/10/2024
NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics , a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, [...]
InnovAge Provides Update on Clinical & Operational Transformations at National PACE Association Annual Conference
11/10/2024
Investments in People, Processes and Tools Deliver Enhanced Experience for InnovAge Participants at Company’s 20 Centers DENVER, Oct. 11, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), a [...]
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024
11/10/2024
LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated [...]
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
11/10/2024
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
11/10/2024
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients [...]
Better Choice Company to Expand into Veterinary Medicine in 2025 Following the Acquisition of SRx Health
11/10/2024
TAMPA, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced expansion plans into veterinary medicine in 2025 [...]
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
11/10/2024
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a clinical-stage biotech company [...]
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
11/10/2024
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis - - Results support advancement of denifanstat into Phase 3 [...]
Curia s’engage envers la norme de neutralité carbone « net zéro » de la SBTi
11/10/2024
Albany, New York, 11 oct. 2024 (GLOBE NEWSWIRE) -- Curia, une organisation de recherche, de développement et de fabrication sous contrat de première importance fait part ce jour de son engagement à réduire ses émissions [...]
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
11/10/2024
Realigning resources to focus on clinical advancement of Selected TIL therapy Reducing employee headcount by approximately 60% Streamlining operations with cash runway expected to extend into 2Q 2026 SAN DIEGO, Oct. 11 [...]
Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella
11/10/2024
Sanofi en discussions pour céder une participation majoritaire dans Opella Paris, 11 octobre 2024 . Sanofi a annoncé aujourd'hui avoir entamé des négociations avec CD&R pour la cession potentielle d’une [...]
Press Release: Sanofi in discussions to sell a controlling stake in Opella
11/10/2024
Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024 . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake [...]
Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella
11/10/2024
Sanofi en discussions pour céder une participation majoritaire dans Opella Paris, 11 octobre 2024 . Sanofi a annoncé aujourd'hui avoir entamé des négociations avec CD&R pour la cession potentielle d’une [...]
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
11/10/2024
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a clinical-stage biotech company [...]
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
11/10/2024
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term growth [...]
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/2024
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]

Pages